Affidea

Coin ingestion is a frequent reason for paediatric radiology referrals, with most cases resolving spontaneously without complications. This imaging case report describes the diagnosis and conservative management of a 2-year-old boy who accidentally ingested a two-Kwacha coin at a public hospital in Zambia. The child remained asymptomatic throughout his hospital and home stay, allowing for a non-invasive approach involving serial plain film radiographs to monitor the coin’s progression through the gastrointestinal tract. Over three days, imaging confirmed the coin’s movement from the oesophagus to the mid-abdomen, culminating in its natural expulsion on the fourth day. This case highlights the crucial role of plain film radiography in both diagnosing and monitoring foreign body ingestion in children, particularly in low-resource settings. It also highlights significant systemic challenges, including the lack of paediatric radiographers, the absence of national paediatric imaging guidelines, a critical shortage of radiologists, and the unavailability of electronic systems for patient data and radiographic image management. Despite these limitations, the successful outcome supports existing evidence that asymptomatic paediatric patients with coin ingestion can be safely managed through careful observation and serial imaging, thus avoiding the risks associated with invasive procedures and sedation.

BackgroundThe number of thyroid cancer diagnoses has been increasing for several decades, with a significant part of cases being detected incidentally (thyroid incidentaloma, TI) by imaging studies performed for reasons other than thyroid disease, including PET/CT with [18F]FDG. The chacteristics of the detected TI cannot be determined solely on the basis of conventional parameters used in everyday clinical practice, such as SUVmax. In recent years, there has been a growing interest in radiomics, which is a quantitative method of analyzing radiological images based on the analysis of image texture. Textural analysis may be helpful, as it allows to characterize features invisible to the physician with the naked eye.ResultsOf the 54 patients who presented focal [18F]FDG-avid TI and had subsequent fine needle aspiration biopsy, 4 patients were excluded from the analysis due to the unavailability of the final diagnostic information. Hence, in the final analysis, data from 50 patients were used (39 females and 11 males) with a mean age of 58.5 ± 11.26. Of these 50 patients, 11 (22.0%) [18F]FDG-avid nodules were diagnosed as malignant. The performance of the XGBoost model in assessing [18F]FDG-avid TI was similar (0.846 [confidence interval, CI, 95% 0.737–0.956]) to SUVmax (0.797 [CI 95%: 0.622–0.973]; p = 0.60).ConclusionsWith an AI-based algorithm using radiomics features it is possible to detect the malignancy of thyroid nodule. However, no statistically significant differences were observed between the AI and radiomics approach, and when using a conventional measure, i.e., SUVmax.

This study evaluated the efficacy, safety, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of SB16 versus reference denosumab (DEN) up to 18months in postmenopausal osteoporosis (PMO) patients, and assessed outcomes after switching from DEN to SB16 compared to those who continued with DEN or SB16. 457 PMO patients were initially randomized, with 407 re-randomized at Month 12 to either continue DEN (DEN+DEN), switch to SB16 (DEN+SB16), or continue SB16 (SB16+SB16) through Month 18. Efficacy was assessed by the percent change from baseline in bone mineral density (BMD) at the lumbar spine, total hip, and femoral neck. Safety, PD, PK, and immunogenicity were evaluated throughout the study period. Mean percent changes from baseline in lumbar spine, total hip, and femoral neck BMD at Month 18 were comparable across treatment groups, indicating comparable efficacy between SB16 and DEN. The mean percent change in lumbar spine BMD was 6.8% (SB16+SB16), 6.2% (DEN+SB16), and 6.8% (DEN+DEN). Total hip BMD increased by 4.4%, 3.5%, and 4.0%, and femoral neck BMD by 3.4%, 3.1%, and 2.7% for SB16+SB16, DEN+SB16, and DEN+DEN, respectively. Safety profiles were similar among groups, with no new safety concerns identified after switching. Only one patient in the DEN+SB16 group developed non-neutralizing anti-drug antibodies by Month 18, indicating a low immunogenicity risk for SB16. Switching from DEN to SB16 demonstrated comparable efficacy, safety, PD, PK, and immunogenicity in PMO patients relative to those who continued DEN. SB16 was well tolerated over 18months, demonstrating comparable outcomes to DEN.

Cerebral amyloid angiopathy (CAA)-related inflammation (CAA-RI) is a potentially reversible manifestation of CAA, histopathologically characterised by transmural and/or perivascular inflammatory infiltrates. We aimed to identify clinical, radiological and laboratory variables capable of improving or supporting the diagnosis of or predicting/influencing the prognosis of CAA-RI and to retrospectively evaluate different therapeutic approaches. We present clinical and neuroradiological observations in seven unpublished CAA-RI cases, including neuropathological findings in two definite cases. These cases were included in a systematic analysis of probable/definite CAA-RI cases published in the literature up to 31 December 2021. Descriptive and associative analyses were performed, including a set of clinical, radiological and laboratory variables to predict short-term, 6-month and 1-year outcomes and mortality, first on definite and second on an expanded probable/definite CAA-RI cohort. Data on 205 definite and 100 probable cases were analysed. CAA-RI had a younger symptomatic onset than non-inflammatory CAA, without sex preference. Transmural histology was more likely to be associated with the co-localisation of microbleeds with confluent white matter hyperintensities on magnetic resonance imaging (MRI). Incorporating leptomeningeal enhancement and/or sulcal non-nulling on fluid-attenuated inversion recovery (FLAIR) enhanced the sensitivity of the criteria. Cerebrospinal fluid pleocytosis was associated with a decreased probability of clinical improvement and longer term positive outcomes. Future lobar haemorrhage was associated with adverse outcomes, including mortality. Immunosuppression was associated with short-term improvement, with less clear effects on long-term outcomes. The superiority of high-dose over low-dose corticosteroids was not established. This is the largest retrospective associative analysis of published CAA-RI cases and the first to include an expanded probable/definite cohort to identify diagnostic/prognostic markers. We propose points for further crystallisation of the criteria and directions for future prospective studies.

Abstract Introduction: This is a prospective, single-center trial (UCLA-IRB#10-000246) in pediatric patients with high-grade bone or soft tissue sarcoma. The aim was to evaluate FDG-PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX).Methods: Bone or soft tissue sarcoma patients with i) baseline FDG PET/CT within four weeks prior to the start of neo-CTX (PET1), ii) early interim FDG PET/CT (six weeks after the start of neo-CTX (PET2), iii) evaluation of neo-CTX response by histology or MRI, and iv) definitive therapy after neo-CTX (surgery or radiation) were included. Semi-quantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were calculated. Patients with necrosis ≥90% in the excised tumor tissue after surgery or with complete disappearance of the soft tissue component on MRI after neo-CTX were considered responders. The primary endpoint was to evaluate the predictive value of FDG PET/CT parameters at baseline and early during neo-CTX for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if FDG PET/CT can predict the response to neo-CTX assessed by percentage of necrosis in the resected tumor or post-treatment MRI. Primary and secondary outcomes were also evaluated in a sub-population of patients with bone involvement only.Results: Thirty-four consecutive patients were enrolled (10 females; 24 males; median age=15.1 years). 17/34 patients (50%) had Osteosarcoma, 13/34 (38%) Ewing Sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44.1%) and 19/34 (55.9%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p <0.02). ΔMTV was associated with tissue response to neo-CTX (p=0.047). None of the PET1, PET2 or ΔPET parameters were associated with OS. Conclusion: FDG PET/CT performed six weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric bone and soft tissue sarcoma patients.

Abstract Background Q.Clear is a new Bayesian penalised-likelihood PET reconstruction algorithm. It has been documented that Q.Clear increases SUVmax values of different malignant lesions. Purpose. As SUVmax values are crucial for interpretation of PET/CT images in patients with lymphoma, particularly when early and final response to treatment is evaluated, aim of the study was to systematically analyze the impact of the use of Q.Clear on interpretation of PET/CT in patients with lymphoma. Methods 280 18 F-FDG PET/CT scans in patients with lymphoma performed for staging (sPET), for early treatment response (iPET), after the end of treatment (ePET) and when a lymphoma relapse was suspected (rPET) were retrospectively analyzed. Scans separately reconstructed with two algorithms: Q.Clear and OSEM were compared. Results The lymphoma stage was concordantly diagnosed in 69/70 patients with both algorithms in sPET. Discordant assessment of Deauville score (p<0.001) was found in 11 cases (15.7%) of 70 iPET scans and in 11 cases of 70 ePET scans. An upgrade from negative to positive scan by Q.Clear resulted in case of 3 (4.3%) iPET scans and 7 (10.0%) ePET scans that resulted in alteration of management. Results of all 70 r-PET scans were concordant. SUVmax values of the target lymphoma lesions measured with Q.Clear were higher than with OSEM in 88.8% scans. Conclusion Although the Q.Clear algorithm may alter interpretation of PET/CT only in a small proportion of patients, we recommend to use standard OSEM reconstruction for assessment of treatment response.

F-prostate-specific membrane antigen (PSMA) 1007 is one of the most promising radiotracers for PET imaging of relapsing prostate cancer. Minimal urinary clearance seems to be its most valuable and outstanding feature. We present images of biochemically relapsed prostate cancer where F-PSMA-1007 PET/CT (performed to verify an ambiguous finding adjacent to the urinary bladder found in F-FCH PET/CT) proved superior to radiocholine and precisely visualized site of local recurrence.

BackgroundIn Alzheimer’s disease (AD), pathological changes may arise up to 20 years before the onset of dementia. This pre-dementia window provides a unique opportunity for secondary prevention. However, exposing non-demented subjects to putative therapies requires reliable biomarkers for subject selection, stratification, and monitoring of treatment. Neuroimaging allows the detection of early pathological changes, and longitudinal imaging can assess the effect of interventions on markers of molecular pathology and rates of neurodegeneration. This is of particular importance in pre-dementia AD trials, where clinical outcomes have a limited ability to detect treatment effects within the typical time frame of a clinical trial. We review available evidence for the use of neuroimaging in clinical trials in pre-dementia AD. We appraise currently available imaging markers for subject selection, stratification, outcome measures, and safety in the context of such populations.Main bodyAmyloid positron emission tomography (PET) is a validated in-vivo marker of fibrillar amyloid plaques. It is appropriate for inclusion in trials targeting the amyloid pathway, as well as to monitor treatment target engagement. Amyloid PET, however, has limited ability to stage the disease and does not perform well as a prognostic marker within the time frame of a pre-dementia AD trial. Structural magnetic resonance imaging (MRI), providing markers of neurodegeneration, can improve the identification of subjects at risk of imminent decline and hence play a role in subject inclusion. Atrophy rates (either hippocampal or whole brain), which can be reliably derived from structural MRI, are useful in tracking disease progression and have the potential to serve as outcome measures. MRI can also be used to assess comorbid vascular pathology and define homogeneous groups for inclusion or for subject stratification. Finally, MRI also plays an important role in trial safety monitoring, particularly the identification of amyloid-related imaging abnormalities (ARIA). Tau PET to measure neurofibrillary tangle burden is currently under development. Evidence to support the use of advanced MRI markers such as resting-state functional MRI, arterial spin labelling, and diffusion tensor imaging in pre-dementia AD is preliminary and requires further validation.ConclusionWe propose a strategy for longitudinal imaging to track early signs of AD including quantitative amyloid PET and yearly multiparametric MRI.

Shoulder apprehension is related to changes in functional cerebral networks induced by dislocations, peripheral neuromuscular lesions and persistent mechanical glenohumeral instability consisting of micro-motion.All the damage to the osseous and soft-tissue stabilizers of the shoulder, as well as neurologic impairment persisting even after stabilization, must be properly identified in order to offer the best possible treatment to the patient.There is growing evidence supporting the use of a global multimodal approach, involving, on the one hand, shoulder ‘reafferentation’, including proprioception, mirror therapy and even cognitive behavioural approaches, and, on the other hand, surgical stabilization techniques and traditional physical therapy in order to minimize persistent micro-motion, which may help brain healing. This combined management could improve return to sport and avoid dislocation arthropathy in the long term.Cite this article: EFORT Open Rev 2018;3:550-557. DOI: 10.1302/2058-5241.3.180007

Studying olfaction with functional magnetic resonance imaging (fMRI) poses various methodological challenges. This study aimed to investigate the effects of stimulation length and repetition time (TR) on the activation pattern of 4 olfactory brain regions: the anterior and the posterior piriform cortex, the orbitofrontal cortex, and the insula. Twenty-two healthy participants with normal olfaction were examined with fMRI, with 2 stimulation lengths (6 s and 15 s) and 2 TRs (0.901 s and 1.34 s). Data were analyzed using General Linear Model (GLM), Tensorial Independent Component Analysis (TICA), and by plotting the event-related time course of brain activation in the 4 olfactory regions of interest. The statistical analysis of the time courses revealed that short TR was associated with more pronounced signal increase and short stimulation was associated with shorter time to peak signal. Additionally, both long stimulation and short TR were associated with oscillatory time courses, whereas both short stimulation and short TR resulted in more typical time courses. GLM analysis showed that the combination of short stimulation and short TR could result in visually larger activation within these olfactory areas. TICA validated that the tested paradigm was spatially and temporally associated with a functionally connected network that included all 4 olfactory regions. In conclusion, the combination of short stimulation and short TR is associated with higher signal increase and shorter time to peak, making it more amenable to standard GLM-type analyses than long stimulation and long TR, and it should, thus, be preferable for olfactory fMRI.